Drug & intervention
Xalatan
RxCUI 153159
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Background context
Xalatan
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.Clinical trials
17 shownEffect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet CellsNCT04957329 · 2021-09-01
RECRUITINGComparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved LatanoprostNCT04743622 · 2019-04-30
COMPLETEDEvaluating the Efficacy and Safety of Xalost S in Glaucoma Patients.NCT04164459 · 2018-12-19
UNKNOWNA Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of GlaucomaNCT02792803 · 2015-09-01
UNKNOWNSafety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular HypertensionNCT02059278 · 2014-01-01
COMPLETEDA Study of the L-PPDS With Adjunctive Xalatan® Eye Drops in Subjects With OH or OAGNCT01037036 · 2009-12-01
COMPLETEDEffects of Cosopt on IOP and on Ocular Diastolic Perfusion PressureNCT00796198 · 2008-12-01
UNKNOWNHow Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?NCT00798694 · 2008-11-01
COMPLETEDExploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®NCT00799682 · 2008-10-01
COMPLETEDSafety, Efficacy Assessment of Geltim LP® 1 mg/g in Ocular Hypertensive or Glaucomatous Patients.NCT01155219 · 2008-07-01
COMPLETEDDose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular HypertensionNCT00465621 · 2007-03-01
COMPLETEDA Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).NCT00383019 · 2006-11-14
COMPLETEDComparison of Efficacy of Two Groups of Glaucoma Drops (Xalatan vs.Cosopt) in Reducing Eye Pressure Following Laser (SLT)Treatment in the Management of Glaucoma.NCT00440336 · 2006-10-01
UNKNOWNA 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With GlaucomaNCT00277498 · 2005-12-01
COMPLETEDA 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With GlaucomaNCT00159653 · 2005-07-01
COMPLETEDCorneal Versus Conjunctival Delivery Using a Delivery DeviceNCT00143429
WITHDRAWNSafety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery DeviceNCT00283764
WITHDRAWNConditions being studied
Research locations
AtlantaGeorgia, United States2El PasoTexas, United States2HoustonTexas, United States2LouisvilleKentucky, United States2New YorkNew York, United States2PhiladelphiaPennsylvania, United States2TorontoOntario, Canada2AmarilloTexas, United States1Ann ArborMichigan, United States1AustinTexas, United States1BirminghamAlabama, United States1BrooklynNew York, United States1
Leading sponsors
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.5Advanced Glaucoma Specialists1Alcon Research1CHA University1Copenhagen University Hospital, Rigshospitalet1Dr. David Yan1Laboratoires Thea1Mati Therapeutics Inc.1Nephron Pharmaceuticals Corporation1Ophthalmic Consultants of Long Island1Taejoon Pharmaceutical Co., Ltd.1University of Turin, Italy1Wills Eye1
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.